-
- Sign In
- Tests
-
Invitae testsFollow-up testingFrequently ordered panels
- How to order
-
Getting startedEssentialsSponsored programs
- Resources
-
Clinical resourcesEducational materialsWorking together
- Technology
-
Our technologyA new gold standardData sharing
- FAQ
- FOR PATIENTS
- CONTACT
- FAQs / SUPPORT
Genetic testing for hereditary cancer
Comprehensive, affordable, and easy-to-order oncology genetic testing
Start an order
Data suggest that many cancer patients with clinically actionable genetic variants are being overlooked. In fact, patients who do not meet clinical guidelines for genetic testing have positive rates nearly as high as patients who meet guidelines.1 Read more >
We believe there are far more cancer patients who should be considered for genetic testing than are currently receiving testing.
We can help streamline the genetic testing process. Start an order today >
Watch a 6-minute video summarizing this study.
Benefits of testing
Genetic information impacts medical management and prevention
Test options
One of the most comprehensive hereditary cancer test menus on the market
Results
Understanding your patients' results and next steps
Invitae advantage
Easy, affordable, high-quality genetic testing you can count on
Benefits of genetic testing
Genetic testing can uncover actionable findings, leading to a significant change in clinical management.
|
CANCER TREATMENT
|
|
|
FUTURE DIAGNOSES
|
|
|
FAMILY MEMBERS
|
|
Typical testing criteria for insurance coverage
Typically, hereditary cancer tends to present at younger ages or with multiple cancers.
If your patient—or one of their close blood relatives—has any of the following, most insurance providers will cover genetic testing:*
- Diagnosis of cancer younger than expected
- Breast cancer and Ashkenazi Jewish ancestry
- Male breast cancer
- Ovarian cancer
- High-risk, regional, or metastatic prostate cancer
- Multiple primary tumors in the same or different organ system
- Tumor pathology suggestive of a genetic syndrome, as noted in a pathology report
- Strong family history of cancer (typically more than one relative on the same side diagnosed with cancer)
Although the great majority of patients who select insurance billing already pay less than $100 out of pocket with Invitae, our simple out-of-pocket cost estimator can bring peace of mind.
For patients who do not meet their insurance testing criteria, we offer $250 patient-pay pricing.
Invitae Breast Cancer STAT Panel
A curated panel with rapid results in 7 days on average to inform breast surgical decisions
Invitae Common Hereditary Cancers Panel
A commonly-ordered comprehensive cancer panel covering breast, gynecologic, prostate, and GI cancers
Invitae Multi-Cancer Panel
Our largest, most comprehensive cancer panel, maximizing diagnostic yield across eight major organ systems
Additional testing options
- Design and customize your own panels from over 130 genes associated with hereditary cancer risk with results in 10-21 calendar days
- Over 40 individual hereditary cancer condition tests
- Rare genes associated with hereditary cancer not typically offered by most labs
Not sure which panel is right for your patient?
Consult with one of our board-certified genetic counselors, available Monday through Friday, 5 am to 5 pm Pacific, to identify patients who could benefit from testing and differentiate between tests.
Ready to get started? Create an account today.
Create an accountWhat to do with your patients' results
|
|
Positive result Refer to our clinical medical management guide for actionable, gene-specific next steps in HBOC or colorectal cancer. Test blood relatives with Invitae’s family variant testing program. Learn more > |
|
|
Negative result Expand to a larger hereditary cancer panel (if appropriate) within 90 days of receiving results, at no additional charge. View all cancer panels > Our board-certified genetic counselors are available to answer your questions about test results and even counsel your patients directly. Clinical consult > |
Invitae testing is covered by most insurance plans and we will not hold a sample or report while managing insurance claims.
Our $250 patient-pay option and patient assistance program help make high-quality testing accessible.
Option to expand to a larger hereditary cancer panel if needed within 90 days of receiving results, at no additional charge.
Genetic counselors available on demand to help identify patients who could benefit from testing, discuss tough cases, and even counsel your patients directly.
Get started
|
|
1. Request free kits for collecting patient specimens
|
|
|
2. Order a test using Invitae’s HIPAA-compliant online portal or on paper
|
|
|
3. Receive an email when your results are ready (14 days on average)
|
Take the first step by requesting a free specimen collection kit or starting an order today.
Tools for your clinic
Invitae’s reference guides offer direction on when to consider genetic testing and provide management guidelines. We have also created patient resources for you to share with your patients when speaking to them about genetic testing.
CancerCHECK
Identify patients who meet typical criteria for insurance coverage
Family history questionnaire
Collect your patient’s full family history to inform management
Management guidelines
Clinically actionable management guidelines for positive results, gene by gene
Risks and references poster
Gene by gene risks for cancer, categorized by organ system
Have a question or comment? Let us know.
Our team is here to answer your questions about ordering, billing, policies, and logistics as you are becoming familiar with our services.
Subscribe to our mailing list
Stay updated on the latest in hereditary cancer. We will send you information on relevant topics once or twice a month.
*These criteria have been adapted from current professional society guidelines. This is not an exhaustive list. Insurance criteria differ across providers. Patients who fit these criteria are not guaranteed to be covered by insurance for genetic testing.
References:
1. Yang S, Axilbund JE, O’Leary E, Michalski ST, Evans R, Lincoln SE, Esplin ED, Nussbaum RL. Underdiagnosis of hereditary breast and ovarian cancer in Medicare patients: Genetic testing criteria miss the mark. Ann Surg Oncol. 2018;25(10):2925-31.
